GlassScriptPhysician profile
Natalie Zoe Eiland
NPI 1558626556
$2,301.56
in general payments reported to CMS, 2019-2025
26 companies · $624 in 2025
The $624 reported for 2025 was more than what 85% of Obstetrics providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $27.09 · 2021: $529 · 2022: $366 · 2023: $406 · 2024: $229 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,165 · Education: $92.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,165.45 |
| Education | $92.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $557.40 | 2019-2023 | |
| Hologic Sales and Service, LLC | $423.73 | 2021-2025 | Aptima, Sonata Sonography-Guided Transcervical Fibroid Ablation System, Novasure |
| Astellas Pharma US INC | $339.19 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $148.46 | 2019-2024 | |
| Exeltis, USA INC. | $106.73 | 2021-2024 | Slynd |
| Mayne Pharma Commercial LLC | $92.29 | 2021-2025 | |
| Organon LLC | $71.97 | 2023-2024 | Nexplanon |
| Sumitomo Pharma America, INC. | $70.86 | 2023-2025 | Myfembree |
| Medtronic, INC. | $55.01 | 2023-2024 | Interstim, Ligasure |
| Therapeuticsmd, INC. | $46.75 | 2019-2022 | |
| Evofem Biosciences, INC. | $43.03 | 2021 | |
| Applied Medical Resources Corporation | $41.74 | 2024 | |
| Mylan Pharmaceuticals INC. | $40.10 | 2021 | |
| Pfizer INC. | $37.20 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $30.86 | 2021-2024 | Gardasil, Gardasil 9 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $27.60 | 2023 | Wegovy |
| Millicent US INC | $23.51 | 2025 | Femlyv, Intrarosa |
| Biogen, INC. | $21.34 | 2025 | Zurzuvae |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.88 | 2023 | Trulance, Xifaxan |
| Currax Pharmaceuticals LLC | $16.87 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $16.81 | 2023 | Exparel |
| Lilly USA, LLC | $16.47 | 2025 | Mounjaro, Zepbound |
| Minerva Surgical, INC | $15.84 | 2023 | |
| Scynexis, INC. | $14.98 | 2022 | |
| Myovant Sciences INC. | $13.04 | 2021 | |
| Meditrina | $12.90 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Eiland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.